1939Experimental Biology and MedicineRequires access

Comparative Effects of Sulfapyridine and Sulfanilamide in Type II Pneumococcic Infection of Mice

George W. Raiziss, M. Severac, J. C. Moetsch, L. W. Clemence

Open publisher page 3 citations

Abstract

While sulfapyridine is somewhat more potent than sulfanilamide in the treatment of Type II pneumococcic infection in mice, it does not cure the animals, but only delays death. Untreated mice survived the infection for 1 day. Twenty-four percent of sulfanilamide-treated animals lived 2 days, while about an equal number of sulfapyridine-treated animals, namely 26%, survived 4 days. The superiority of sulfapyridine over sulfanilamide is only in the delay of death by 2 days. Similar experiments were made in Types I and III pneumococcic infection, and the results obtained were about the same as in Type II. In view of the reported good results observed with sulfapyridine in the treatment of pneumonia, our findings in experimental pneumococcic infection in mice are less encouraging than in human infection.

About this research paper

What this paper is about

While sulfapyridine is somewhat more potent than sulfanilamide in the treatment of Type II pneumococcic infection in mice, it does not cure the animals, but only delays death. Untreated mice survived the infection for 1 day. Twenty-four percent of sulfanilamide-treated animals lived 2 days, while about an equal number of sulfapyridine-treated animals, namely 26%, survived 4 days. The superiority of sulfapyridine over sulfanilamide is only in the delay of death by 2 days. Similar experiments were made in Types I and III pneumococcic infection, and the results obtained were about the same as in Type II. In view of the reported good results observed with sulfapyridine in the treatment of pneumonia, our findings in experimental pneumococcic infection in mice are less encouraging than in human infection.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

While sulfapyridine is somewhat more potent than sulfanilamide in the treatment of Type II pneumococcic infection in mice, it does not cure the animals, but only delays death. Untreated mice survived the infection for 1 day. Twenty-four percent of sulfanilamide-treated animals lived 2 days, while about an equal number of sulfapyridine-treated animals, namely 26%, survived 4 days. The superiority of sulfapyridine over sulfanilamide is only in the delay of death by 2 days. Similar experiments were made in Types I and III pneumococcic infection, and the results obtained were about the same as in Type II. In view of the reported good results observed with sulfapyridine in the treatment of pneumonia, our findings in experimental pneumococcic infection in mice are less encouraging than in human infection.

Key concepts: Sulfanilamide, Sulfapyridine, Pneumonia, Medicine, Internal medicine, Chemistry, Biochemistry, Organic chemistry

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparative Effects of Sulfapyridine and Sulfanilamide in Type II Pneumococcic Infection of Mice — Research Paper | ScholarLens